Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01315951
Other study ID # ME 10 0054
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date March 2011
Est. completion date March 2012

Study information

Verified date May 2024
Source Ascension Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this research is to demonstrate the use of petroleum jelly in prevention of nonscalp seborrheic dermatitis exacerbations at the first signs of a flare. In doing so, it will decrease the chronic use of topical steroids. The use of petrolatum should have favorable outcomes for patients, without the side-effects.


Description:

Nonscalp seborrheic dermatitis (NSSD) is typically a benign inflammatory process of the skin that affects oil rich areas including in and between eyebrows, paranasal area, behind ears, over the sternum, and groin. While these lesions typically come and go without proposing a threat to the patient, they can be socially debilitating, and psychologically distressing. The mainstay treatment for an exacerbation of NSSD is topical steroids. Topical steroids are very effective and useful to patient's who are desperately seeking treatment. However, most family practitioners are reluctant to prescribe or recommend topical steroids for chronic conditions like NSSD due to the potential side-effects including permanent atrophy of the skin. NSSD has an unknown etiology. However, one of its biggest risk factors appears to be dry skin due to its increase in incidence during colder seasons, and with use of alcohol-containing topicals. Naturally occurring skin yeast (ie Malassezia) are also thought to play a part. Petrolatum is considered a skin protectant and has a strong ability to hold moisture in skin. Along with restricting water from leaving skin, it also decreases most air from contacting the skin. This may slow the growth and activity of skin yeast that are typically considered facultative anaerobes. A patient diagnosed with nonscalp seborrheic dermatitis will be consented into the study and given instructions on the petroleum treatment. This includes wetting the affected area, blotting dry, and then applying petrolatum to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient will come back to the office for follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome. Pictures will be taken at each encounter and used to measure progress through one mm graphs. Patients will not be identifiable in these pictures, and they will be labeled with the patient's given ID number.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date March 2012
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age 18-75 years old who are patients of the Genesys East Flint Clinic and have been diagnosed with recurrent NSSD - Patients are to use the petrolatum treatment strictly for the initial symptoms of NSSD: Excessive flaking, and erythematous macules or papules - Patients who are able to attend the follow-up appointments for assessment - Patients are to have the doctor's confidence that that patient will correctly implement the treatment plan Exclusion Criteria: - Patients not in the 18-75 years of age range. - Patients who are receiving treatment for their seborrheic dermatitis (Scalp or nonscalp) elsewhere. - Patients who have not demonstrated recurrent NSSD. - Patients who are unable to commit to a follow-up appointments for assessment. - Patients who do not have the physician's confidence in implementing the studies treatment plan effectively. - Patient's who are unable/unwilling to have petrolatum on affected area for at least a 6 hour length of time.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Petroleum Jelly
Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.

Locations

Country Name City State
United States Genesys East Flint Campus Burton Michigan

Sponsors (1)

Lead Sponsor Collaborator
Ascension Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis Petroleum jelly will be applied to the areas of the face affected by Nonscalp Seborrheic Dermatitis every other night for four weeks. Patients will be seen in the office at one week, two weeks, and one month during the course of the treatment. Pictures will be taken at each visit to determine the progress of the treatment. 4 weeks
Secondary Patient Satisfaction ofTreatment Patients will be surveyed initially when they are consented asking about their personal history of nonscalp seborrheic dermatitis including triggers and previous and current treatment measures. 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT01703793 - Safety and Efficacy Study in Subjects With Seborrheic Dermatitis Phase 2
Completed NCT01203189 - Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo N/A
Completed NCT00991198 - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Phase 2
Completed NCT03567980 - A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Phase 4
Recruiting NCT03688971 - Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Phase 2
Recruiting NCT01139749 - Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Phase 4
Completed NCT05105139 - Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Completed NCT01591070 - Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Phase 4
Completed NCT05787860 - Ruxolitinib in Seborrheic Dermatitis Phase 2
Completed NCT00403559 - A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis Phase 2
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Recruiting NCT05942248 - The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis N/A
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Recruiting NCT05319444 - Cleansing Device for the Treatment of Scalp and Hair Conditions N/A
Completed NCT04445987 - Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis Phase 2
Completed NCT04973228 - Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) Phase 3
Completed NCT03114111 - Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Early Phase 1
Completed NCT02656368 - Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis N/A
Completed NCT00830908 - HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis N/A
Completed NCT02349854 - Neurobiology of the Scalp in Seborrheic Dermatitis N/A